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miR-433-3p Negatively Regulates Bone Formation and Targets Critical for 
Osteoblast Function 
 
John Garcia, MPH, MSc 
University of Connecticut, 2020 
 
Osteoblastic differentiation is tightly controlled by multiple signaling pathways 
associated with key transcription factors, as well as a number of microRNAs (miRNAs). miRNAs 
are small noncoding RNAs that function in the post-transcriptional regulation of gene 
expression. While clinical strategies to combat the reduction in bone density have often 
centered on impeding further bone resorption, this strategy neglects to promote bone 
formation, a component which is particularly problematic in the aging population. miRNAs 
could serve to bridge that gap, as potential therapeutic candidates. Several studies have 
established that miRNAs can direct osteoprogenitors towards an osteoblastic lineage through 
modulation of Wnt, MAPK, TGFβ and BMP signaling. Thus, this thesis consists of 2 independent 
manuscripts. First, a primary research article details novel mechanisms by which one particular 
miRNA, miR-433-3p, regulates osteoblastic differentiation via modulation of Wnt, MAPK, PTH 
and glucocorticoid signaling. Second, a comprehensive review documents how miRNAs regulate 
TGFβ and BMP signaling to promote or repress osteoblast formation and function. 
Regarding miR-433-3p, this miRNA can specifically target Runx2 and is repressed by 
BMP2 signaling. Herein, we demonstrate that miR-433-3p is progressively decreased during 
osteoblastic differentiation of primary mouse bone marrow stromal cells in vitro, and we 
confirm its negative regulation of this process. Although repressors of osteoblastic 
differentiation often promote adipogenesis, inhibition of miR-433-3p did not affect adipocyte 
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differentiation in vitro. Additionally, since multiple pathways regulate osteogenesis, using 3' 
UTR-Luciferase reporter assays five novel miR-433 targets involved in PTH, MAPK, Wnt, and 
glucocorticoid signaling pathways were validated.  
In vivo, expression of a miR-433-3p inhibitor or tough decoy in the osteoblastic lineage 
increased trabecular bone volume. Mice expressing the miR-433 tough decoy displayed 
increased bone formation without alterations in osteoblast or osteoclast numbers or surface, 
indicating an impact on osteoblast activity. Overall, we demonstrated that miR-433 is a negative 
regulator of bone formation in vivo, targeting key bone-anabolic pathways including those 
involved in PTH signaling, MAPK, Wnt and endogenous glucocorticoids. Local delivery of miR-
433 inhibitor could present a strategy for the management of bone loss disorders and bone 
defect repair.  
Having a wide understanding of the signaling pathways, differentiating factors, and the 
mechanisms necessary for the miRNA-mediated induction of multipotent cells along an 
osteoblastic lineage is key for the effective utilization of miRNAs as therapeutic candidates in 
the management of bone disorders. Thus, this thesis also contains a review that showcases 
miRNAs regulating TGFβ and BMP signaling pathways in bone forming osteoblasts, to illustrate 
their interaction with and impact on bone formation. BMP signaling is particularly relevant to 








The goal of the work presented in this thesis is to illustrate the central role of microRNAs in 
the control of bone-forming osteoblasts and to disseminate novel observations on the function 
of one miRNA, miR-433, in the osteoblast lineage. 
 
Osteoblasts are terminally differentiated cells with mesenchymal origins, known to 
possess pivotal roles in sustaining bone microstructure and homeostasis 1. These bone forming 
cells, with the ability to synthesize and secrete bone matrix proteins, are implicated in the 
pathophysiology of various bone disorders, especially osteoporosis 1. Osteoblasts originate 
from mesenchymal stem cells (MSCs), which are non-hematopoietic multipotent cells within 
bone marrow. Bone marrow-derived MSCs (BMSCs) are capable of differentiating into multiple 
cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes and have been applied 
medically for diverse indications ranging from bone regeneration to cardiac repair 2.  
Differentiation of MSCs into osteoblasts is carefully controlled by transcription factors such as 
Runx2, and signaling pathways such as BMP, TGF, and Wnt 1. 
 
Multiple studies have shown that miRNAs can direct mesenchymal stem cells (MCSs) 
towards an osteoblastic lineage through modulation of Wnt, TGFβ and BMP signaling 3. miRNAs 
are small non-coding RNAs that function in the post-transcriptional regulation of gene 
expression and are involved in many biological processes such as self-renewal, proliferation, 
function, and differentiation 4,5,6,7,8. miRNAs exert their regulatory role through direct 
interaction with mRNAs that contain sequences complementary to the miRNA 4,5,6,7,8. miRNAs 
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interacting with their target mRNA regulate gene expression through the inhibition of 
translation and/or enhancement of mRNA degradation 4,5,6,7,8. In the mesenchymal lineage, 
miRNAs can promote or inhibit differentiation toward the osteoblastic fate through modulation 
of signaling pathways important in bone formation 4,5,6,7,8. 
 
Chapter 2 of this thesis is a primary research article in which we describe new data on the 
function of miR-433 in osteoblast lineage, including its ability to regulate signaling pathways 
that converge on bone formation. We demonstrate that miR-433-3p is progressively decreased 
during osteoblastic differentiation of primary mouse BMSCs in vitro, and we confirm its 
negative regulation of this process. Additionally, since multiple pathways regulate osteogenesis, 
we identify and validate five novel miR-433 targets involved in PTH, MAPK, Wnt and 
glucocorticoid signaling. 
 
Chapter 3 of this thesis is a comprehensive review article highlighting components of the 
TGF/BMP signaling family and their regulation by specific miRNAs. The TGF/BMP signaling 
pathway is particularly relevant to bone health and therapeutics because members of this 
superfamily are implicated in the function and metabolism of bone cells 9. The role of TGF in 
osteoblasts is context dependent. It can exert a biphasic effect on osteoblastic differentiation 
by promoting activation, proliferation, and early commitment of pre-osteoblasts at an early 
state, while impeding terminal osteoblast differentiation at later stages, especially during 
mineralization 10,11. BMPs, another member of the TGFβ superfamily, play a key role in bone 
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formation due to their strong osteogenic capacities and can promote the restoration of critical-
size bone defects 12,13. Use of miRNA based therapeutics is also discussed. 
 
Overall, by deepening our understanding of the mechanisms that regulate TGFβ/BMP 
signaling, we can develop appropriate therapeutic strategies aimed at treating skeletal 
pathologies. Having a wide knowledge of the signaling pathways, differentiation factors, and 
mechanisms necessary for the miRNA-mediated induction of multipotent cells along an 
osteoblastic lineage is critical for the effective utilization of miRNAs as therapeutic candidates in 





















miR-433-3p Suppresses Bone Formation and mRNAs that are Critical for Osteoblast Function 
 
Abstract 
microRNAs (miRNAs) are key post-transcriptional regulators of osteoblastic commitment 
and differentiation. miR-433-3p can target Runx2 and is repressed by BMP2 signaling. Here, we 
demonstrate that miR-433-3p is progressively decreased during osteoblastic differentiation of 
primary mouse bone marrow stromal cells in vitro, and we confirm its negative regulation of 
this process. Although repressors of osteoblastic differentiation often promote adipogenesis, 
inhibition of miR-433-3p did not affect adipocyte differentiation in vitro.  
Multiple pathways regulate osteogenesis. Using 3' UTR-Luciferase reporter assays, five 
novel miR-433 targets involved in PTH, MAPK, Wnt, and glucocorticoid signaling pathways were 
validated. We demonstrate that CREB1 is a miR-433 target, and this transcription factor 
mediates key signaling downstream of PTH receptor activation. We also show that miR-433-3p 
targets HSD11B1, the enzyme that locally converts inactive glucocorticoids to their active form. 
miR-433-3p dampens glucocorticoid signaling, and targeting of HSD11B1 could contribute to 
this phenomenon. Moreover, miR-433 targets RSPO3, a LGR ligand that enhances Wnt 
signaling. Notably, canonical Wnt signaling is also blunted by miR-433 activity. In the MAPK 
signaling pathway, p38a/MAPK14 and its upstream kinase MKK3/MAP2K3 are miR-433-3p 
targets, whereas JNK1 is not. P38 MAPK signaling promotes osteogenesis; it is activated by 
BMP2 and it also integrates signals from Wnt and PTH receptor activation.  
In vivo, expression of a miR-433-3p inhibitor or tough decoy in the osteoblastic lineage 
increased trabecular bone volume. Mice expressing the miR-433 tough decoy displayed 
increased bone formation without alterations in osteoblast or osteoclast numbers or surface, 
 5 
indicating an impact on osteoblast activity. Overall, we demonstrated that miR-433 is a negative 
regulator of bone formation in vivo, targeting key bone-anabolic pathways including those 
involved in PTH signaling, MAPK, Wnt and endogenous glucocorticoids. Local delivery of a miR-
433 inhibitor could present a strategy for the management of bone loss disorders and bone 
defect repair.  
 
Introduction 
Bone undergoes continuous cycles of remodeling necessary to maintain its structural 
integrity, adapt to mechanical use, meet metabolic demands, and facilitate fracture repair 
1,14,15,16. The ongoing remodeling cycle is orchestrated by bone-resorptive osteoclasts, bone-
forming osteoblasts, and osteocytes that act as mechano-sensors imbedded in the bone 1,14,15. 
An imbalance between bone formation and resorption can compromise bone mass and quality 
14,15,16. The gene expression programs that regulate bone formation and resorption are 
informed by cell-to-cell communication between native bone cells, as well as signals from 
growth factors, cytokines, and hormones 4,5,6,7,14,15. These signals regulate gene expression at 
multiple levels, utilizing transcriptional, post-transcriptional and post-translational mechanisms. 
In the last decade, microRNA (miRNA)-mediated mechanisms have emerged as central to the 
regulation of bone resorption and formation 1,4,16,17,18. 
 
miRNAs are small noncoding RNAs that function in the post-transcriptional regulation of 
gene expression 4,5,6,7,8. miRNAs exert their regulatory role through direct interaction with 
mRNAs that contain sequences complementary to the miRNA 4,5,6,7,8. When loaded into the 
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RNA-induced silencing complex (RISC), miRNAs act as a “guiding strand” to recruit the RISC to 
complementary regions within the target mRNAs 5,6,7,8,19. miRNAs interacting with their target 
mRNAs regulate gene expression through the inhibition of translation and/or enhancement of 
mRNA degradation 4,5,6,7,8. These 21-24 base RNAs are involved in many biological processes 
such as self-renewal, proliferation, function, and differentiation 4,5,6,7. In the mesenchymal 
lineage, miRNAs can promote or inhibit differentiation toward the osteoblastic fate through 
modulation of signaling pathways important in bone formation, including the Wnt, TGFβ and 
BMP pathways 4,5,6,7,8. A single miRNA can potentially target many distinct mRNAs. Frequently, 
miRNAs target multiple mRNAs involved in the same or a correlated pathway, to modify the 
tempo and amplitude of signaling programs, making them excellent therapeutic targets. 
 
Although the impact of some miRNAs on the skeleton is well documented, other miRNAs, 
such as miR-433, are less well understood. miR-433-3p is expressed in the osteoblast lineage, 
but not in osteoclasts 20. We initially found that miR-433-3p could differentially target a single 
nucleotide polymorphism (SNP) in human osteonectin (SPARC), an abundant non-collagenous 
bone matrix protein that regulates osteoblast differentiation and survival 21,22. Osteonectin 
plays a key role in maintenance of bone mass, and this osteonectin 3’ UTR SNP, that mediated 
differential binding of miR-433-3p, was associated with in bone density in a cohort of Caucasian 
men with idiopathic osteoporosis 21,22. A novel set of human osteonectin 3’ UTR knock-in mice 
validated that this SNP regulates bone volume and the anabolic bone response to intermittent 
parathyroid hormone (PTH) administration 22.  
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Additional evidence for a prominent role for miR-433 in skeletal biology comes from 
another SNP study, in which a nucleotide substitution in the 3’ UTR of histone deacetylase 6 
(HDAC6) negates post-transcriptional regulation by miR-433. This results in the overexpression 
of the HDAC6 protein in a novel form of dominant X-linked human chondrodysplasia, and marks 
one of the first examples of a skeletal disease caused by a dysregulation of miRNA-mediated 
regulation of mRNAs 23,24. In vitro studies in osteoblastic cells have validated additional miR-433 
targets important for bone formation, including Runx2 25,26. miR-433 can also target Hif1α and 
Igf1, genes responsible for the coupling of angiogenic and osteogenic activity needed for bone 
formation and osteoblast proliferation, and the enhancement osteoblast differentiation 26.  
 
The miR-433 locus is located within the Glt2-Dio3 miRNA mega-cluster on human 
chromosome 14, a genomic locus that is conserved on mouse chromosome 12. The miR-433 
gene structure and transcriptional regulation are highly conserved across mammalian species 
suggesting that it may exert similar regulatory effects 27,28,29,30. miR-433 is located within the 
anti-retrotransposon-like 1 (RTL1) transcript, which negatively regulates RTL1, a protein coding 
gene that plays an important role in placenta development 31. While mutations and deletions 
within the human 14q32.2 imprinted region, which contains the miR-433 locus, are associated 
with impaired growth as well as facial and thoracic abnormalities, the contribution of miR-433 
to this phenotype is unclear 32.  
 
We sought to better understand the role of miR-433-3p in osteoblastic lineage commitment 
in vitro and bone formation in vivo. Herein, we show that, using C3H10T1/2 mesenchymal cells 
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stably transduced with a miR-433-3p “tough decoy” (TuD) to suppress endogenous miR-433-3p 
activity, miR-433 is a negative regulator of osteoblastic differentiation, but does not impact 
adipogenesis. Further, we validated novel miR-433-3p targets in multiple pathways playing an 
important role in osteoblastogenesis and bone formation, revealing potential mechanisms by 
which miR-433 functions as a negative regulator of these processes. Lastly, using mice 
expressing a miR-433TuD in osteogenic cells, we show that this miRNA decreases osteoblastic 
activity and that its inhibition promotes bone formation.  
 
Methods 
Animal Care  
We previously described a line of C57BL/6 mice expressing a transgene cassette in which 
a 3.6-kb fragment of the rat Col1A1 promoter and 1.6 kb of the first intron drives expression of 
the tdTomato reporter gene containing miR-433TuDs within its 3’-UTR 33,34. The sequence for 
the miR-433 transgene TuD cassette is reported in Supplemental Table 1. Wild type and miR-
433TuD littermates were housed under specific pathogen-free conditions within the Center for 
Comparative Medicine at UConn Health. Only male mice were used for these studies. All mice 
were kept under a 12-h light/dark cycle and were provided with standard chow and water ad 
libitum. All animal protocols were reviewed and approved by the Institutional Animal Care and 
Use Committee (IACUC) at UConn Health.  
 
Cell Culture  
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A multipotent mouse mesenchymal cell line, C3H10T1/2 clone 8, was obtained from the 
American Type Culture Collection (ATCC® CCL-226™, Manassas, VA) and cultured in DMEM 
(Gibco Life Technologies, Carlsbad, CA), 10% heat-inactivated Fetal Bovine Serum (FBS, Lonza, 
Basel, Switzerland), and 1% Penicillin/Streptomycin. Primary bone marrow stromal cells 
(BMSCs) from 8 week old male C57Bl/6 mice were isolated from tibias and femurs by 
centrifugation and cultured in αMEM (Gibco Life Technologies), 10% heat-inactivated FBS, and 
1% Penicillin/Streptomycin 35.  
 
Osteogenic Differentiation  
Osteogenic differentiation of C3H10T1/2 cells was induced by culture in DMEM, 10% 
heat-inactivated FBS, 1% Penicillin/Streptomycin, 100 μg/ml Ascorbic Acid (Sigma-Aldrich, St. 
Louis, MO), 2 μM Purmorphamine (Sigma-Aldrich), 8 mM β-glycerophosphate (Sigma-Aldrich), 
and 50 ng/ml BMP2 (gift from Medtronic, Dublin, Ireland). Once primary BMSCs reached 
confluence, they were cultured in αMEM, 10% heat-inactivated FBS, 1% 
Penicillin/Streptomycin, 50 μg/ml Ascorbic Acid, and 5 mM β-glycerophosphate.  
Mineral deposition was measured by staining cultures with 1% alizarin red S (Sigma-
Aldrich). Stain was then extracted and quantified by at absorbance 405 nm 22. Cultures were 
also stained for alkaline phosphatase activity using an Alkaline Phosphatase kit (#86R, Sigma-
Aldrich), according to the manufacturer’s instructions. 
 
Adipogenic Differentiation  
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Adipogenic differentiation was achieved using αMEM media supplemented with 10% 
FBS, 500 nM rosiglitazone (Sigma-Aldrich) and 1 μM insulin (Sigma-Aldrich). Cells were then 
stained with 0.5% Oil Red O solution to visualize fat droplets.  
 
Generation of an Inducible miR-433 Tough Decoy Model  
To knockdown activity of miR-433 in vitro, C3H10T1/2 cells were stably transduced with 
a lentiviral vector (pSLIK) in which a doxycycline (Dox)-inducible promoter drives expression of 
construct expressing either a miR-433 TuD (containing complementary miR-433 binding sites) 
or a non-targeting TuD (containing C. elegans miR-67 binding sites) 26. Pools of stably 
transduced cells were selected for hygromycin resistance. The sequence for the miR-433 and 
non-targeting TuD is reported in Supplemental Table 1. The single lentivector for inducible 
knockdown (pSLIK) contains a ubiquitin C promoter which drives constitutive expression of 
reverse Tet transactivator (rtTA3) (Addgene, Cambridge, MA) 36. Doxycycline (Dox) treatment 
stimulates the rtTA to drive transcription of TRE, allowing for inducible expression of the TuD. 
Once expressed, the miR-433TuD acts as an inhibitor for endogenous miR-433 activity. The 1 
µg/ml dose of Dox used in these studies was previously shown to maximally induce expression 
of the decoy construct 26. 
 
Static and Dynamic Histomorphometry  
For dynamic histomorphometry, mice were injected with Alizarin-3-methyliminodiacetic 
acid (30 mg/kg; Sigma-Aldrich) and Calcein (10 mg/kg; Sigma-Aldrich) 10 and 3 days prior to 
euthanasia, respectively. Post-harvest, femurs were fixed for 7 days in 4% paraformaldehyde at 
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4°C. After fixation, femurs were placed in 30% sucrose for 24-36 hours, embedded in O.C.T. 
(Thermofisher, Waltham, MA) and flash frozen in 2-methylbutane (Fisher, Hampton, NH). 7 μm 
sections were collected using a Leica cryostat and a Cryofilm II tape transfer system (Section 
Lab Co. Ltd., Hiroshima, Japan), and cross-linked to glass slides using Norland Optical Adhesive. 
For static histomorphometry, femurs were fixed 7 days in 4% paraformaldehyde at 4°C. After 
fixation, femurs were decalcified for 21 days in a 14% EDTA and 2.7% NH4OH. Femurs were 
then dehydrated, embedded in paraffin, and sectioned using a Leica microtome. 7 μm sections 
were stained for Tartrate-resistant Acid Phosphatase (TRAP) activity, stain to visualize 
osteoclasts, and counterstained with hematoxylin. Dynamic and static histomorphometry 
parameters were quantified using Osteomeasure software (OsteoMetrics), measuring 200 μm 
from the growth plate and cortical bone, as advised by the Nomenclature Committee of the 
American Society for Bone and Mineral Research 37. All samples were blinded prior to analysis. 
 
microCT 
 Femurs from miR-433TuD mice and wild type controls were fixed in 70% ethanol at 4°C 
until imaging. The distal region of the femur was analyzed at 8 μm voxel resolution using micro-
CT (UConn Health microCT Core: μCT40, Scanco Medical AG, Wangen-Brüttisellen, Switzerland) 
to quantify trabecular and cortical morphometry 38. Samples were blinded prior to analysis. 
 
RNA Extraction and qPCR 
RNA was extracted from cell cultures using TRIzol Reagent (Life Technologies, Carlsbad, 
CA). Total RNA was quantified, treated with RQ1 DNase (Promega, Madison, WI), and subjected 
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to random hexamer-primed reverse transcription using Moloney murine leukemia virus-reverse 
transcriptase (Invitrogen, Carlsbad, CA). Gene expression was quantified by qPCR with iQ SYBR 
Green Supermix (Bio-Rad) and normalized to 18S rRNA levels.  
miRNA levels were analyzed using TaqMan MicroRNA Assays (Life Technologies, 
Carlsbad, CA). RNA was reverse transcribed using mature miRNA-specific primers to generate 
cDNA and microRNA expression was quantified by qPCR and normalized to snoRNA 202 levels. 
In vitro studies were performed at 2-3 times and each experiment contained at least 4 
biological replicates, all assayed in duplicate.  
 
Luciferase Constructs  
 Using gene-specific PCR primers, the 3’ UTR of MKK3 (cDNA bases 1214-2142), p38 
(cDNA bases1527-3570), RSPO3 (cDNA bases 1370-2350), JNK1 (cDNA bases 3570-4480), CREB1 
(cDNA bases 1211-2160 and 4826-5873), and Hsd11β1 (cDNA bases 943-1292) were amplified 
from mouse genomic DNA. Primer sequences are reported in Supplemental Table 2. Using 
specific restriction enzymes, the amplified fragments were cloned into the multicloning site of 
the pMIR REPORT Luciferase plasmid (Ambion, Austin, TX), in which a Cytomegalovirus (CMV) 
promoter drives expression of the Luciferase reporter. All constructs were verified by Sanger 
sequencing (GeneWiz, South Plainfield, NJ).  
  
Luciferase Assays 
 C3H10T1/2 cells were plated at 15,000 cells/cm2. After 24 hours, cells were co-
transfected with the Luciferase constructs containing the 3’ UTR of target mRNA, a 
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constitutively expressing β-Galactosidase construct that serves as a control for transfection 
efficiency (GenBank accession number U02451) (Clontech, Mountain View, CA), and 80 nM 
mirVana™ anti-miR-433-3p or a mirVana™ negative control #1 (non-targeting) miRNA hairpin 
inhibitors (Ambion). Transient transfection was accomplished using BioT transfection reagent 
(1.5μl:1μg BioT:nucleic acid; Bioland Scientific, Paramount, CA), according to the 
manufacturer’s instructions. 24 hours post-transfection, growth medium was renewed. After 24 
hours recovery, cells were serum deprived overnight prior to harvest using a Reporter Lysis 
Buffer (Promega, Madison, WI). To examine canonical Wnt signaling, cells were co-transfected 
with miRNA inhibitors and a TOPFlash plasmid (M50 Super 8x TOPFlash Plasmid #12456; 
Addgene). After recovery, cells were serum-deprived overnight prior to treatment with 30-50 
ng/ml recombinant human Wnt-3a (R&D Systems Minneapolis, MN) or vehicle for 6 hours 
before harvest. Samples were analyzed for Luciferase activity using a Luciferase Assay System 
(Promega) and normalized to β-Galactosidase activity using Galacton® (Applied Biosystems, 




 Data presented in bar graphs are mean ± standard deviation, with n ≥ 3, as listed in the 
figure legends. For data presented as box-and-whisker plots, the top and bottom of each box 
represent the 75% and 25% quartiles, respectively, whereas the middle line represents the 
mean. The whiskers denote the minimum and maximum of the data set, and the open circles or 
“x” represent individual outliers. Statistical significance was determined using a Student’s t test 
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or a two tailed ANOVA with Bonferroni post-hoc test, as appropriate (KaleidaGraph, Synergy 
Software, Reading, PA). 
 
Results  
miR-433 Decreases During Osteogenic Differentiation  
 In C3H10T1/2 cells, miR-433 was suggested to be a negative regulator of osteoblast 
differentiation 25. However, the expression of miR-433 during osteogenesis in primary cells has 
not been examined. Therefore, primary BMSCs were cultured in an osteogenic cocktail for up to 
4 weeks. When comparing to confluence, expression of osteogenic markers genes alkaline 
phosphatase (AP; early marker for osteoblast differentiation), Runt-related transcriptional 
factors 2 (Runx2; key transcription master associated with osteoblasts), and osteocalcin (Oc; 
Bglap; terminal osteoblast differentiation marker) was increased during differentiation (Figure  
 
Figure 2.1 miR-433 decreases during osteogenic differentiation of bone marrow stromal cells 
Bone marrow stromal cells were differentiated with β-glycerophosphate and ascorbic acid for 
up to 4 weeks. (A) Alkaline phosphatase (Ap), Runx2, and osteocalcin (Oc) mRNA expression. 
(B) Alkaline phosphatase (AP) and Alizarin Red S staining. (C) miR-433-3p expression.  
















Figure 2.2. miR-433 decoy enhances osteogenic differentiation in vitro 
C3H10T1/2 cells were stably transduced with a Dox-inducible construct carrying either a non-
targeting or miR-433 decoy in the 3’ UTR of the reporter gene GFP. The miR-433-3p binding 
sites are denoted in red (A). Non-targeting and miR-433 decoy cells were cultured with BMP2 
for up to 3 weeks, in the absence or presence of 1 µg/ml Dox. Alkaline phosphatase (Ap) 
mRNA expression in (B) non-targeting and (E) miR-433 decoy cells. Runx2 mRNA expression in 
(C) non-targeting and (F) miR-433 decoy cells. Osteocalcin mRNA expression in (D) non-
targeting and (G) miR-433 decoy cells. # = significantly different from day 0, p < 0.05. * = 
significantly different from corresponding no Dox control, p < 0.05. (n=8)  
Data produced by Spenser Smith 
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 2.1A). Alkaline phosphatase activity and mineralized matrix deposition were also substantially 
increased, as indicated by alkaline phosphatase and Alizarin Red S staining respectively (Figure  
 2.1B). Contrary to osteogenic markers genes, miR-433 expression was progressively decreased 
during osteogenic differentiation, with a 70% reduction noted at week 3 (Figure 2.1C).  
 
miR-433 Negatively Regulates Osteoblastic Differentiation in vitro  
 To determine whether miR-433 impacts osteogenic differentiation, we used a previously 
described stably transduced C3H10T1/2 cell line expressing a Doxycycline (Dox) inducible miR-
433TuD 26,36 (Figure 2.2A). The TuD acts as an inhibitor for endogenous miR-433 and its activity 
phenocopies that of a transiently transfected miR-433-3p inhibitor, in regard to its ability to 
relieve repression of miR-433 on its targets 26. 
 
 To induce osteogenic differentiation, the stably transduced non-targeting miRNA TuD 
(control) or miR-433TuD C3H10T1/2 cells were cultured for up to 3 weeks in an osteogenic 
cocktail containing 50 ng/ml bone morphogenetic protein 2 (BMP2). In cells expressing the non-
targeting decoy, osteogenic marker genes alkaline phosphatase, Runx2, and osteocalcin were 
increased at all time points and were not altered by the presence of Dox (Figure 2.2B,C,D). In 
the absence of Dox, osteogenic gene expression in the miR-433TuD cells was similar to that of 
the non-targeting controls. However, upon treatment with Dox, there was a significant 
enhancement in the expression of osteogenic marker genes alkaline phosphatase, Runx2, and 
osteocalcin (Figure 2.2E,F,G). Growth curves for the non-targeting and miR-433TuD cells 
cultured in the presence or absence of Dox were superimposable, suggesting that enhanced cell 
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number did not play a role in the impact of miR-433 inhibition on osteoblastogenesis in vitro 
(data not shown). Overall, miR-433 acts as a negative regulator of osteogenesis in vitro.  
 
miR-433 Does Not Alter Adipogenic Differentiation in vitro  
 Since osteoblasts and adipocytes can arise from a common progenitor within the bone 
marrow and marrow adipogenesis is often inversely correlated with bone mass, we examined 
the role of miR-433 in adipogenic differentiation 39. Primary BMSC cultures were stimulated 
with an adipogenic cocktail containing rosiglitazone and insulin for up to 9 days and mRNA 
levels for adipogenic differentiation markers Cebpα (CCAAT/enhancer binding protein α), Pparγ 
(peroxisome proliferator activated receptor γ), and Fabp4 (fatty acid binding protein 4) were 
examined. Adipogenic marker genes were higher at all time points compared to day 0 (Figure 
2.3A). Oil red O staining showed increasing lipid droplet accumulation throughout the 9 days of 
differentiation (Figure 2.3C). However, miR-433 expression was not significantly altered over 
the course of adipogenic differentiation in BMSCs (Figure 2.3B).  
 
Although miR-433 expression did not change during adipogenesis, it could still exert a 
regulatory role on adipogenic differentiation. To examine this, non-targeting and miR-433TuD 
cells were cultured with the adipogenic cocktail, in the absence or presence of Dox. In non-
targeting TuD cells, Cebpα and Pparγ mRNA expression were induced, but they were not 
altered by treatment with Dox (Figure 2.3D, E). Similarly, in miR-433TuD cells, the expression of 
adipogenic marker genes was not altered in the presence or absence of Dox (Figure 2.3F, G), 




Figure 2.3. miR-433 is not altered during adipogenic differentiation of bone marrow stromal 
cells 
Primary BMSCs were differentiated with rosiglitazone and insulin for up to 9 days. (A) Cebpα, 
Pparγ, and Fabp4 mRNA expression. (B) miR-433 expression. (C) Oil Red O staining. Non-targeting 
and miR-433 decoy cells were differentiated in the absence of presence of 1 µg/ml Dox. Cebpα 
mRNA expression in (D) nontargeting and (F) miR-433 decoy cells. Pparγ mRNA expression in (E) 
non-targeting and (G) miR-433 decoy cells. # = significantly different from day 0, p < 0.05. (n=8)   
Data produced by Spenser Smith  
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miR-433 Targets in the Osteoblast Lineage   
 Runx2 is critical for osteoblastic differentiation and was previously shown to be a miR-
433 target 25. However, each miRNA can potentially target hundreds of miRNAs. Therefore, we 
sought to validate other miR-433-3p targets that may have an impact on osteoblast function. 
We used an in silico approach (miRanda, TargetScan, RNAhybrid) to identify potential novel 
targets within pathways important for osteoblasts, and our analysis suggested that genes active 
in PTH, glucocorticoid, MAPK (Mitogen-activated Protein Kinase) and Wnt signaling pathways 
could be potential miR-433 targets (Figure 2.4A).  
 
PTH acts in the osteoblastic lineage to promote bone formation, as well as bone 
resorption 40,41. Creb1 (cAMP Responsive Element Binding Protein 1) is a key transcription factor 
mediating major effects of PTH signaling on gene expression in osteoblasts 40,41. Whereas 
several studies in humans demonstrated that Creb1 is targeted by miR-433, it is not yet known 
whether this regulatory action is conserved in mice  42,43,44. Our bioinformatic analysis revealed 
two potential miR-433 binding sites in the Creb1 3’ UTR. Therefore, both proximal and a distal 
Luciferase-Creb1 3’ UTR constructs were created in the pMIR-REPORT reporter plasmid, to test 
binding site function (Figure 2.4A). C3H10T1/2 cells were transiently co-transfected reporter 
plasmids along with either a non-targeting or miR-433 inhibitor. Co-transfection with the miR-
433 inhibitor relieved repression of both proximal and distal Luciferase-Creb1 3’ UTR 
constructs, demonstrating independent miR-433-responsive regulatory regions in the Creb1 3’ 
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UTR and also establishing that this regulatory mechanism active in humans is conserved in mice 
(Figure 2.4B).  
 
We recently showed that miR-433 dampens glucocorticoid receptor signaling, and our 
bioinformatics analysis suggested that Hsd11β1 (11β-hydroxysteroid dehydrogenase 1) (Figure 
2.4A), the enzyme that allows cells to locally convert inactive glucocorticoids to their active 
form, could be a miR-433 target 26,45,46,47 . Therefore, we created an Hsd11β1 3’ UTR reporter 
plasmid, which was co-transfected into C3H10T1/2 cells with either a non-targeting or miR-433 
inhibitor. miR-433 inhibition resulted in a significant increase in luciferase activity, validating 
Hsd11β1 as a novel miR-433 target (Figure 2.4C). 
MAPKs play a critical role in transducing extracellular signals to intracellular effectors. 
The response of osteoblasts to PTH, TGFβ, BMP2, and Wnt ligands requires the activity of 
MAPKs 48,49,50,51,53,54. MAPKs are particularly well studied in bone and have a positive impact on 
osteoblast differentiation and function 55. Bioinformatic analysis suggested that several 
components of the MAPK signaling pathway could be directly targeted by miR-433-3p, including 
MKK3 (Mitogen-activated Protein Kinase Kinase 3), p38 (Mitogen-activated Protein Kinase 14) 
and JNK1 (Mitogen-activated Protein Kinase 8) (Figure 2.4A) 56,57,58,59. To determine whether 
miR-433 targets these murine RNAs, 3’ UTR luciferase reporter constructs were created and 
transfected into C3H10T1/2 cells with non-targeting or miR-433 inhibitor, and luciferase activity 
was quantified. Whereas miR-433 inhibition did not affect the luciferase activity of the JNK1 3’ 
UTR construct, it did relieve repression of the p38 3’UTR and that of MKK3, the upstream 





Seed Binding Region 3’Untranslated Region mfe Value (kcal/mol) 
MKK3 1219 
target 5’  G   C    C           C 3’ 
            GCC AGGA CCCA C UGGU     
            UGG UCCU GGGU G ACUA     





target 5’ C  UG       AAGA  UUC      G 3’ 
           AC  UGAGGGG    CC   UCAUGG     
           UG  GCUCCUC    GG   AGUACU     




target 5’  A      AAUU   AUU   CU       U 3’ 
            GCUGAG    AGC   CCA  UCAUGGU     
            UGGCUC    UCG   GGU  AGUACUA     





target 5’ A                     A 3’ 
           GCGCC AGGA    AUCAUGA     
           UGUGG UCCU    UAGUACU     





target 5’ G    AUAAUCCU         GAAGG        A 3’ 
           GCAU        UGAGGGGUU     UAUCAUGA     
           UGUG        GCUCCUCGG     GUAGUACU     
miRNA  3’                                    A 5’ 
-26.8 
Hsd11β1 1175 
target 5’ C    UU       GCA       A 3’ 
           CACU  GGGGCCU   GUUGUGA     
           GUGG  CCUCGGG   UAGUACU     
miRNA  3’ U    CU                 A 5’ 
-28.1 
RSPO3 1379 
target 5’ C UG     UUACU  AGA         G 3’ 
           C  CGAGG     GU   C UCAUGAU     
           G  GCUCC     CG   G AGUACUA     







Canonical Wnt signaling plays an important role in the regulation of bone homeostasis 
and is considered a central positive regulator of osteogenesis 15,60,61. In adults, Wnt signaling 
can avert the differentiation shift of pre-osteoblasts to adipocytes and can inhibit excessive 
osteoclastogenesis by regulating osteoblasts 62,63. Our bioinformatic analysis suggested that 
several components of the Wnt signaling pathway could be directly targeted by miR-433, with 
RSPO3 (R-spondin 3) (Figure 2.4A) being a particularly strong candidate. R-spondins are LGR 
ligands that act as enhancers of Wnt signaling by preventing Wnt receptor degradation 64,65,66. 
Co-transfection of the miR-433 inhibitor relieved repression of the Luciferase 3’ UTR construct, 
validating Rspo3 as a novel miR-433 target (Figure 2.4G).  
 
Since R-spondins serve to enhance Wnt signaling, we determined whether inhibition of 
miR-433 had an impact on canonical Wnt signaling in vitro. To do so, we transiently transfected 
cells with a TOPflash vector, to report stimulus-dependent Wnt signaling activity, along with 
either a non-targeting or miR-433 inhibitor. The TOPflash reporter contains 7 repeats of a 
TCF/LEF binding site driving expression of Luciferase; its transcription is activated upon 
stimulation of Wnt signaling. To induce Wnt signaling, transfected cells were treated with 30 or 
50 ng/ml Wnt3a. The lower dose of Wnt3a resulted in a similar induction of luciferase activity in 
cells treated with either non-targeting or miR-433 inhibitor. In cells transfected with the non-
Figure 2.4. miR-433 targets glucocorticoid, MAPK and canonical Wnt signaling pathways 
(A) Interaction of miR-433-3p with potential targets as predicted by RNAhybrid. Activity of the (B) CREB1, (C) 
Hsd11β1, (D) JNK1, (E) MKK3, (F) p38α, and (G) RSPO3 luciferase-3’ UTR reporter constructs in transiently 
transfected C3H10T1/2 cells, in the presence of miR-433 or non-targeting miRNA inhibitor. (H) Activity of the 
Wnt responsive TopFLASH luciferase reporter in C3H10T1/2 cells co-transfected with a non-targeting or miR-
433 inhibitor. N=6 
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targeting inhibitor, treatment with the higher dose of Wnt3a did not augment promoter 
activity. However, cells treated with miR-433 inhibitor had significantly increased luciferase 
activity compared with the low dose or with the non-targeting control. These data indicate that 
miR-433 dampens Wnt signaling (Figure 2.4H). 
 
In Vivo Impact of miR-433 Decoy  
Many traditional approaches for investigating gene function in vivo center on loss of 
function studies through gene inactivation. Given the location of miR-433 in the genome, a 
knock-out strategy could compromise RTL1, anti-RTL1, or its neighboring miRNA, miR-127, 
presenting potentially confounding variables. To circumvent these issues, we employed a tough 
decoy (TuD) inhibitor approach, in which a transgene cassette containing 3 copies of a miR-433-
3p tough decoy within the 3’ UTR of the reporter gene tdTomato, and driven by the rat Col1a1 
promoter (Figure 2.5A). The ability these hairpin-shaped tough decoys to suppress endogenous 
miRNA activity has been well characterized and shown to be more effective than the more 
traditional “bulged sponge”. While miRNA decoys can decrease the abundance of mature 
miRNAs, sequestration of miRNA-mRNA complexes in P-bodies may also provide additional 
relief from miRNA targeting 34,67,68.  
 
miR-433 is rhythmically expressed in bone, and using this miR-433TuD mouse model, we 
had previously demonstrated that miR-433 dampens circadian rhythm in bone tissue 26. 
Further, bone RNA from the 8 week old males had increased levels of Runx2 and osteocalcin 
RNA, but the skeletal phenotype of the miR-433 decoy mice was not examined in detail. 
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Therefore, we used microCT analysis to assess the microarchitecture of femurs from mice at 8 
and 20 weeks of age, representing growing and skeletally mature animals 69. Since our previous 
studies were performed in males and preliminary analyses did not suggest an obvious skeletal 
phenotype in females (data not shown), all subsequent experiments were carried out in males. 
Eight weeks of age is a time of peak trabecular bone volume in B6 mice, and there was no 
difference in cortical or trabecular bone parameters between wild-type (WT) and TuD mice (TG) 
at this age (Figure 2.5B-E) 69.  
 
From 8 to 20 weeks of age, WT mice displayed a significant increase in cortical thickness, 
an effect that trended higher in the miR-433TuD mice (Figure 2.5B). In contrast, as the mice 
became older, we observed the expected decrease in trabecular bone volume (20% loss) in the 
20 week WT group when compared to 8 weeks (Figure 2.5C). However, this bone volume loss 
was attenuated in the 20 week TuD group (7% loss, not significant) (Figure 2.5C). Trabecular 
number decreased between 8 and 20 weeks of age in both TuD and WT groups, with no 
difference between the genotypes (Figure 2.5D). Trabecular spacing was similarly unaffected by 
genotype (data not shown). While there was no significant difference in trabecular thickness 
from 8 to 20 weeks in the WT mice, this parameter was increased 17% between 8 and 20 weeks 
in TuD mice (Figure 2.5E), an effect that could contribute to attenuation of bone volume loss in 









 Since TuD mice had increased trabecular bone volume at 20 weeks, histomorphometry 
was conducted at this age, to examine the impact miR-433 inhibition on cellular parameters 
regulating bone homeostasis and their activity. Static histomorphometry did not reveal a 
significant difference in osteoblast or osteoclast surface, eroded surface, or osteoblast and 
osteoclast numbers between WT and TuD mice (Figure 2.6A-E). However, dynamic 
histomorphometry showed a significant increase in mineral apposition rate, bone formation 
rate, and mineralizing surface in mice expressing the miR-433 TuD compared to the WT control 
(Figure 2.6F-H). Together, these data demonstrate that miR-433 is a negative regulator of bone 
formation in vivo. 
  
Figure 2.5. microCT analysis of femurs from 8 and 20 week male wild type (WT) and miR-433TuD 
(TG) mice.  
(A) Schematic of miR-433 decoy transgene cassette. A 3.6-kb fragment of the rat Col1a1 gene plus the 
first intron drive expression of the reporter gene tdTomato and a 3-UTR containing three copies of a 
miR-433 tough decoy, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), 
and bovine growth hormone polyadenylation signal (polyA). (B) Cortical thickness, (C) Bone Volume 
Fraction (BV/TV), (D) Trabecular Number, and (E) Trabecular Thickness. µCT reconstructions of (F) 






Figure 2.6. Histomorphometric analysis of femurs from 20 week male wild type (WT) and miR-433TuD 
mice (TG) 
Static histomorphometry (A) Osteoblast number per bone perimeter (N.Ob/B.Pm), (B) Osteoblast surface 
(Ob.S/BS), (C) Eroded surface per bone surface (ES/BS), (D) Osteoclast surface per bone surface (Oc.S/BS, 
and (E) Osteoclast number per bone perimeter (N.Oc/B.Pm). Dynamic histomorphometry (F) Mineral 
Apposition Rate, (G) Bone Formation Rate, and (H) Mineralizing Surface. (I) Representative static 
histomorphometry images for WT and TG. Femurs from 20 week male mice. (J) Representative dynamic 
histomorphometry images. Femurs from 20 week male mice. Alizarin complexone (red) and calcein 






 In this study, we showed that miR-433-3p is decreased during the osteoblastic 
differentiation of primary BMSCs, and confirmed its role as a negative regulator of this process. 
Although negative regulators of osteoblastic differentiation often promote adipogenesis, 
inhibition of miR-433 did not affect adipocyte differentiation 70. Whereas miR-433 was 
previously shown to target Runx2, a master transcription factor for osteoblastogenesis, 
additional miR-433 targets important for the osteoblast lineage were poorly described. Here, 
we validated 5 novel miR-433 targets spanning PTH, MAPK, Wnt and glucocorticoid signaling 
pathways. Moreover, we demonstrated that miR-433 is a negative regulator of osteoblast 
function in vivo, impacting trabecular and cortical bone compartments.   
 
While miR-433-3p decreases during osteogenesis (Figure 2.1C), but we did not define 
underlying mechanisms in primary cells. However, like most genes, transcription of miRNA loci 
are regulated by epigenetic mechanisms and the binding of regulatory elements by 
transcription factors and transcription factor modifiers. Since miRNAs undergo processing steps 
in both the nucleus and cytoplasm, levels of mature miRNAs can also be regulated in a post-
transcriptional manner 71. Regarding miR-433, information on the mechanisms regulating its 
expression remains fairly limited. Presently, there is little evidence that miR-433-3p is 
differentially regulated at the level of pri- or pre-miRNA processing. In contrast, at the 
transcriptional level, the miR-433 locus is activated by the orphan nuclear receptor estrogen 
related receptor γ (ERRγ, NR3B3), a transcription factor known to inhibit osteogenesis and 
decrease of chondrocyte proliferation 25,26,30,72. In contrast, miR-433 transcription can be 
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repressed by small heterodimer partner (SHP, NR0B2), which promotes osteoblast 
differentiation 30,72,73. An epigenetic program has also been documented to regulate miR-433 
transcription 42. For example, the miR-433 promoter contains CpG islands which can be 
hypermethylated, and treatment with a DNA methylation inhibitor can induce its expression 
42,44,74.  
 
Expression of a miR-433TuD increased bone formation rate in vivo and osteogenic 
marker gene expression in vitro; there are multiple pathways regulating osteoblast function and 
considerable crosstalk among these osteogenic pathways. We identified novel miR-433-3p 
targets active in PTH, MAPK, Wnt and glucocorticoid signaling pathways, all of which can be 
bone anabolic. For example, in the PTH pathway, we established murine Creb1 as a miR-433 
target (Figure 2.4B). This leucine zipper transcription factor mediates key signaling downstream 
of PTH receptor activation 40,41,75. In osteoblastic cells, PTH binding to its receptor causes the 
activation of adenylate cyclase and production of cAMP. This leads to the activation of protein 
kinase A (PKA) and the subsequent phosphorylation of CREB1 76. Once activated, CREB1 binds 
to the cAMP response element and triggers a cascade of gene expression that promotes 
osteoblast proliferation, commitment to the lineage, and maturation, while inhibiting apoptosis 
40,41,77,78,79,80. Whether miR-433 decoy mice are more sensitive to PTH signaling remains an area 
of interest. 
 Endogenous, physiological glucocorticoid signaling plays a positive role in the acquisition 
of bone mass in vivo and promotes the expression of mature osteoblast markers in vitro 81,82. 
Moreover, glucocorticoid receptor signaling is important for normal fracture repair 83. We 
 30 
identified Hsd11b1 as a novel miR-433 target (Figure 2.4C). At the pre-receptor level, 
glucocorticoids are regulated locally by Hsd11β isozymes, of which Hsd11β1 is prominently 
expressed in osteoblast and osteoclasts, catalyzing the conversion of inactive glucocorticoids to 
their active form 45,46,47,84. It is well known that miRNAs can cause modest changes in the 
expression of multiple targets within a single signaling pathway, to mediate significant changes 
responsiveness. We had previously established that inhibition of miR-433-3p activity increased 
sensitivity to glucocorticoids, while others demonstrated that the glucocorticoid receptor 
(Nr3c1) is directly targeted by miR-433 26,85. That miR-433-3p targets multiple pathway 
components critical for promoting glucocorticoid signaling suggests that this miRNA plays an 
important role in limiting responsiveness. Indeed, in vivo endogenous glucocorticoids play a 
central role in synchronizing peripheral circadian clocks, and in miR-433 decoy mice, the 
amplitude of rhythmic gene expression in bone is increased. Increased Hsd11β1 expression due 
to decreased miR-433 could amplify levels of active glucocorticoids within cells, and contribute 
to the increased sensitivity to glucocorticoid receptor signaling. 
In contrast, glucocorticoid excess is one of the leading causes of secondary osteoporosis, 
enhancing osteoblast apoptosis and decreasing IGF1 levels, inhibiting bone formation 84,86. 
Interestingly, Hsd11β1 is implicated in age-related bone loss, as its activity increases with age 
84,87,88. Moreover, polymorphisms in the Hsd11β1 gene have been associated with osteoporosis 
in postmenopausal women 45,89,90,91. Further, Hsd11β1 has also been associated in the efficacy 
of glucocorticoid treatment, since the sensitivity to therapeutic glucocorticoids is dependent on 
its expression and activity 45,46,92,93. These translational studies illustrate the potential 
importance of regulating local glucocorticoid activity in bone and other tissues.  
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 Several components in the MAPK signaling pathway, MKK3 and p38α, are directly 
targeted by miR-433 (Figure 2.4E, F). MAPKs function as critical signal transducers in response 
to a wide spectrum of extracellular stimuli, impacting osteoblast differentiation and function 
55,94,95. The MAPK family contains three well characterized subfamilies: extracellular signal–
regulated kinases (ERKs) which control cell division, c-Jun amino-terminal kinases (JNKs) which 
phosphorylate multiple transcription factors, and p38 MAPKs, which activated by TGF family 
ligands, inflammatory cytokines and environmental stressors 55,95. In cardiac fibroblasts, miR-
433 was shown to target the human JNK1 3’ UTR 57. However, our data indicate that this 
regulation was not conserved in mice (Figure 2.4D), unlike the cross-species conservation of 
Creb1 targeting by miR-433-3p (Figure 2.4B).  
 
In MAPK signaling, MKK3 is an intermediate member of the phosphor-relay system that 
selectively activates p38 MAP kinase, but not p38β or JNK or ERK MAPK family members 96,97. 
Within the p38 MAPKs, p38 is noted to be a key regulator of bone homeostasis, regulating 
transcription factors needed for osteoblastogenesis, such as Dlx5, Runx2, and Sp7/Osx 97. 
Studies using p38 inhibitors in cell lines or primary osteoblasts have shown that the p38 
signaling pathway can regulate alkaline phosphatase activity and mineralization in response to 
BMP2, TGFβ, PTH, and Wnt ligands 97. The ability of miR-433 to target both p38 and its 
upstream activating kinase, MKK3, suggest that this signaling pathway may play an important 
role in the effect of miR-433 on the osteoblast lineage (Figure 2.4E-F). 
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Inhibition of miR-433 increased responsiveness to canonical Wnt signaling, and we 
verified that RSPO3 is a novel miR-433 target (Figure 2.4G, H). RSPO3 belongs to the R-spondin 
family of Wnt agonists, which potentiate canonical Wnt signaling by reducing Wnt receptor 
turnover, enhancing subsequent βcatenin stabilization 65,66,98,99. Although R-spondins vary in 
their functional effects with respect to the skeleton, they are expressed in the developing 
skeleton, contributing to limb formation 65,66. During early development, RSPO3 is highly 
expressed within the primitive streak, neural tube, brain, limb bud, heart, kidney, and small 
intestine 66,100. In mice, Rspo3 disruption during development results in embryonic lethality due 
to angiogenic defects in the placenta 65,66,101,102,103. Rspo2 and Rspo3 are suggested to be 
functionally redundant, and loss of Rspo2 in osteoblasts decreases bone formation and 
trabecular bone volume 65. While there may be other miR-433 targets within the Wnt pathway 
that are yet to be validated, we show that inhibition of miR-433 activity promotes canonical 
Wnt signaling, which could contribute to the increased bone formation and bone volume seen 
in miR-433 decoy mice.  
 
While we validated miR-433-3p targets in seemingly diverse pathways, these pathways 
all have a positive impact on osteoblast differentiation and function, and many have points of 
intersection and convergence (Figure 2.7). Moreover, a single miRNA can have tens to hundreds 
of mRNA targets. Here, we report on the targets that we identified, not on all miR-433-3p 
targets that may be important in osteoblasts. For the most part, miRNAs cause modest changes 
in the expression of multiple targets, to mediate a more pronounced effect on cell physiology. 
Therefore, it is may be difficult to tie the function of a miRNA to the regulation of single 
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pathway or to a single component of a pathway. However, at the risk of over simplifying 
complex pathways and limiting the interpretation of our data by considering only known miR-
433-3p targets, we assembled a working model to illustrate some of the interactions among 
miR-433 target pathways. For example, inhibition of miR-433 increases sensitivity to 
glucocorticoids and increases the expression of the direct glucocorticoid receptor target gene  
DUSP1 (dual specificity protein 
phosphatase 1) 26. One way in 
which glucocorticoid receptor 
signaling interacts with MAPK 
is by DUSP1-mediated 
dephosphorylation of p38α 104. 
Moreover, Runx2 is a miR-433 
target that can be phosphorylated and activated by p38α, which is also miR-433 target 105. 
Transcription mediated by accumulation of nuclear βcatenin has profound effects on 
osteoblastic differentiation, as does transcriptional programs activated by CREB1 
15,40,41,77,78,79,80,. However, bidirectional crosstalk between PTH/cAMP and Wnt signaling 
pathways occurs, resulting in cooperative induction of gene transcription 106. Validation of 
additional miR-433 targets is central to a better understanding of its function in osteoblasts and 
in other tissues.   
 
Indeed, miR-433 expression is not bone specific; it is broadly although not ubiquitously 
expressed. Much of the previous work on miR-433 has involved its role in extra-skeletal 
 
Figure 2.7. Simplified working model of miR-433-3p target 
interaction pathways. Direct miR-433 targets are in red font.  
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pathologies. For example, miR-433 is reported to be up-regulated in cases of renal, liver, and 
cardiac fibrosis, while down-regulated in cases of gastric carcinoma, Hepatitis B virus-associated 
hepatocellular carcinoma, and in visceral adipose tissue from patients with non-alcoholic 
steatohepatitis 57,107,108,109,110,111. miR-433 levels have been linked with tumorigenicity and 
neoplastic progression, as either a promoter or suppressor 42,44,74,112. The novel miR-433 targets 
validated in this study are likely to have implications in other tissues in which they are co-
expressed with miR-433.  
 
With a thorough understanding of key molecular mechanisms regulating osteoblast 
differentiation and function, new strategies aimed at increasing bone formation could be 
developed. The ability of miRNAs to regulate the differentiation of multipotent cells along an 
osteoblastic lineage has become evident, highlighting their potential clinical applications as 
orthobiologic agents 113. Not only could miRNA-based therapeutics be used in the management 
of skeletal disorders, but they could help treat difficult fractures and accelerate normal 
physiological fracture repair 113. While naked nucleic acids are prone to degradation, a number 
of viral and non-viral carriers could be utilized to protect, deliver, and increase the transfection 
efficiency of miRNA‐based therapeutics 113,114. Although viral vectors result in stable expression 
and higher transfection efficiencies, they can be immunogenic, toxic, and have higher 
production cost 113,115. Whilst non-viral vectors are safer and nontoxic, they have lower 
transfection efficiencies 113,116.  
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Importantly, there are a number of studies describing biomaterials that can be used as 
miRNA‐delivery‐based scaffolds. These biomaterials, including calcium phosphate, peptides, 
nanoparticles, lipid‐based or polymeric‐based carriers, and polymeric hydrogels, have the 
potential to increase transfection efficiencies without drawbacks associated with viral delivery 
113,117,118. Some of which have already shown preclinical success in treating bone defects 113. 
Overall, we demonstrated that miR-433 is a negative regulator of bone formation, targeting key 
bone-anabolic pathways. Local delivery of miR-433 inhibitor could present a strategy for the 
management of bone loss disorders and bone defect repair.  
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microRNAs Regulating TGF and BMP Signaling in the Osteoblast Lineage 
 
Abstract 
Osteoblastic differentiation is tightly controlled by a number of signaling pathways 
associated with key transcription factors, as well as many microRNAs (miRNAs). miRNAs are 
small noncoding RNAs that function in the post-transcriptional regulation of gene expression. 
While clinical strategies to combat the reduction in bone density have often centered on 
impeding further bone resorption, these strategies neglect to promote bone formation, a 
component which is particularly problematic in the aging population. miRNAs could serve to 
bridge that gap, as potential therapeutic candidates. Multiple studies have established that 
miRNAs can direct osteoprogenitors towards an osteoblastic lineage through modulation of 
TGFβ and BMP signaling. miRNAs can target ligands such as the TGFβ isoforms (TGFβ1, TGFβ2, 
and TGFβ3) and BMP7, signaling receptors such as TGFβR1 and BMPR2, and signal transducers 
such as SMAD1-5. Having a wide understanding of the signaling pathways, differentiation 
factors, and the mechanisms necessary for the miRNA-mediated induction of multipotent cells 
along an osteoblastic lineage is key for the effective utilization of miRNAs as therapeutic 
candidates in the management of bone disorders. Thus, this review aims to showcase miRNAs 
regulating to the anabolic activity of bone forming osteoblasts, to illustrate their interaction 
with the TGFβ and BMP signaling pathway and effects on bone formation. Therapeutic 




Bone is a highly dynamic mineralized tissue that plays two key anatomical roles: metabolic 
and mechanical 14,119. Its metabolic role consists of the ability of bone to regulate serum 
electrolytes through the release of mineral from the bone matrix, and energy metabolism via 
release of osteocalcin in response to endocrine signals 14,119,120. In its mechanical role, bone 
supports locomotion while protecting soft tissues and major organs 14,16,119. Bone undergoes 
continuous remodeling, which is a complex process necessary for fracture healing and skeletal 
adaptation to mechanical use 1,14,15. During normal remodeling, bone-resorptive osteoclasts, 
bone-forming osteoblasts, and mechano-sensing osteocytes orchestrate the remodeling 
process by replacing old bone with new, in order to maintain bone homeostasis and structural 
integrity 1,14,15. Aside from intricate cell-to-cell communication, bone remodeling can be 
controlled locally by growth factors or cytokines, and systemically through calcitonin and 
various endocrine signals – all contributing to bone homeostasis 14,15. Dysregulation in the 
remodeling process could result in an imbalance between bone resorption and formation, 
which impacts bone homeostasis and compromises structural integrity, highlighting the need to 
study the function and regulation of bone cells and their progenitors 14,15,16.  
 
While osteocytes play a key role in the remodeling process, bone resorption and formation 
are carried out by two main cell types: osteoclasts and osteoblasts, respectively 1,14,15. 
Osteoclasts are multinucleated cells that originate from mononuclear cells of the hematopoietic 
lineage and are driven into an osteoclastic fate primarily by two cytokines, Receptor Activator 
of Nuclear Factor Kappa-B Ligand (RANKL) and Macrophage Colony Stimulating Factor (M-CSF) 
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14,15,16. In contrast, osteoblasts originate from multipotent mesenchymal stem cells (MCSs) 
1,14,15. The commitment and differentiation of MSCs into an osteoblastic lineage is tightly 
regulated by a number of signaling pathways including the wingless‐type (Wnt), transforming 
growth factor-beta (TGFβ), and bone morphogenetic protein (BMP) pathways 1,14,15,16.  
 
Osteoblasts play a pivotal role in sustaining bone microstructure and homeostasis 1,14. 
Having the ability to synthesize bone matrix proteins, inadequate osteoblast number or activity 
are implicated in the pathophysiology of various bone disorders, including osteoporosis 1,14,15. 
Clinical strategies to combat osteoporosis have often centered on impeding further bone 
resorption 15. While this strategy can attenuate bone loss, it neglects to promote bone-
formation, a component which is particularly problematic in the aging population 1,15. During 
aging, there is a gradual decrease of osteoprogenitors, osteoblastic differentiation, and a 
reduction of hormone levels such as estrogen and testosterone; this favors bone loss and 
increases the risk of fracture 16,121. Fortunately, microRNA (miRNA)-based therapeutics could 
serve to bridge the present gap in bone anabolics.  
 
miRNAs are noncoding RNAs that function in the post-transcriptional regulation of gene 
expression 4,5,6,7,8. miRNA-mediated post-transcriptional regulation is managed primarily 
through their direct interaction with mRNAs that contain sequences complementary to the 
miRNA, resulting in inhibition of translation and/or enhancement of mRNA degradation 4,5,6,7,8. 
These small 21-24 base RNAs are involved in many biological processes such as self-renewal, 
proliferation, function, and differentiation 4,5,6,7. Recent studies have established that miRNAs 
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can direct MCSs towards an osteoblastic lineage through modulation of TGFβ and BMP 
signaling – both of which play important regulatory roles in bone formation, bone healing, and 
osteoblastogenesis 3. The TGFβ/BMP family is complex; its ligands have both postive and 
negative effects on osteoblast commitment, differentiation and activity. Having a wide 
understanding of the signaling pathways, differentiation factors, and the mechanisms necessary 
for the miRNA mediated induction of multipotent cells along an osteoblastic lineage is key for 
the effective utilization of miRNAs as therapeutic candidates in the management of bone 
disorders such as osteoporosis. 
 
Thus, this review aims to showcase miRNAs contributing to the regulation of bone forming 
osteoblasts through their effects on the TGFβ and BMP pathways, with a focus on ligands, 
receptors and SMAD-mediated signaling. While transcriptional and post-transcriptional 
mechanisms regulate this pathway, it is also regulated by mechanisms that moderate ligand 
availability and activation. One limitation of our review is that we do not consider miRNA 
regulation of genes affecting the activity or availabilty of TGFβ family ligands, nor do we address 
miRNA regulation of non-canonical signal transduction mechanisms. However, the goal of this 
work is to provide a basis for broadly understanding the contribution of miRNAs to the 
modulation of TGFβ, BMP and activin signaling in the osteoblast lineage, and the rationale for 
potential therapeutic strategies. Therefore, the search strategy for this systematic review was 
restricted to validated miRNA targets within the canonical TGFβ and BMP signaling pathways; 
miRNA-target interactions based only bioinformatics will not be discussed. 
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To set the stage, we will briefly summarize miRNA biogenesis and function, as well as the 
TGF and BMP signaling pathways, as an introduction to the players involved. 
 
miRNAs, TGF and BMP Basics 
MicroRNAs 
Mature miRNAs are derived from primary transcripts (pri‐miRNA) produced principally by 
RNA polymerase II (Figure 3.1) 5,6,7,122,123 . While in the nucleus, the pri-miRNA undergoes the 
first round of cleavage by a multiprotein microprocessor complex that includes the RNase III 
enzyme Drosha and RNA-binding protein DGCR8 (DiGeorge syndrome critical region 
8)/Pasha(Partner of Drosha) 5,6,7,8,19,122,123. This initial cleavage results in a precursor miRNA (pre-
miRNA) which is subsequently transported to cytoplasm by Exportin-5 and Ran-GTP 1,7,8,122,123. 
Once in the cytoplasm, the 70-80 nucleotide pre-miRNA is further cleaved by an RNase III 
enzyme, Dicer, to produce a mature miRNA duplex 5,6,7,8,19,122,123. This miRNA duplex is then 
unwound, isolating the mature singled-stranded miRNA (guiding strand) from its 
complementary passenger strand, which is degraded 5,6,7,8,19,122,123. The remaining single-
stranded miRNA “guiding strand” is loaded onto an RNA-induced silencing complex (RISC) which 
contains Dicer, one of the Argonaute family of proteins (a central component and key player), 
and additional RNA-binding proteins 5,6,7,8,19,122,123. As part of this complex, the miRNA facilitates 
the sequence-specific recruitment of RISC to complementary regions within the target mRNA 
5,7,8,122,123. With this sequence-specific interaction, miRNAs can regulate gene expression by 
destabilizing mRNAs through cleavage, or deadenylation of the target mRNAs or through the 
inhibition of protein translation 3,5,7, 19,122,123,124. 
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TGF Superfamily Signaling 
The TGFβ superfamily is composed of over 30 members including TGFβs, BMPs, growth 
differentiation factors (GDFs), and activins 125,126. Members of TGFβ superfamily play key roles 
in the regulation of bone homeostasis 9,125,127. Additionally, they can regulate skeletal muscle 
repair, cellular immune responses, and even prolong cell survival through the suppression of 
programmed cell death in different cell types 3,9,125,127,128. There are 3 TGFβ isoforms in 
 
Figure 3.1 miRNA Biogenesis 
miRNAs are transcribed by RNA-polymerase II into primary transcripts called pri-mRNA. The pri-miRNA is 
cleaved into pre-miRNA by Drosha and its RNA-binding partner DGCR8. The pre-miRNA is subsequently 
exported by Exportin-5 out of the nucleus, where it is further sliced by another RNase III enzyme, Dicer, to 
result in a miRNA duplex. The miRNA duplex is unwound and the mature single strand is incorporated into 
the RISC complex. Depending on the degree of complementary to the target mRNAs, once in the RISC 
complex, the mature miRNA can lead to translational repression, mRNA deadenylation, and/or mRNA 
degradation. 
 42 
mammals (TGFβI, TGFβII, and TGFβIII), all of which are implicated in the function and 
metabolism of bone cells 9. TGFβ has also been documented to exert a biphasic effect on 
osteoblastic differentiation by promoting activation, proliferation, and early commitment of 
pre-osteoblasts at an early state, while impeding terminal osteoblast differentiation at later 
stages, especially during mineralization 10,11.  
 
BMPs are the largest subdivision of the TGFβ superfamily, and are composed of nearly 30 
different human proteins 126,129,130. Due to the differences among members of the BMP 
subdivision, in terms of mechanics and downstream cellular effects, the term BMP is restricted 
to molecules that elicit activation of the canonical BMP signaling pathway, limiting the list to 
roughly 12 BMP ligands in humans 126. BMPs play a pivotal role in bone formation during 
development and they promote the restoration of critical-size bone defects 12. A number of 
BMPs display strong osteogenic capacities 13. For example, addition of BMP2 can increase 
osteocalcin and bone formation, whereas a severe impairment of osteogenesis results from the 
loss of both BMP2 and 4 131,132. BMP7 is also osteogenic, mediating an increase in the 
expression of osteoblastic markers and mineralization in vitro 132,133,134. 
TGFβ superfamily ligands can initiate signaling cascades via both SMAD-dependent 
(canonical pathway; Figure 3.2) and a SMAD-independent (non-canonical) pathways 1,3,135,136,137. 
In canonical signaling, SMAD family members facilitate signal transduction from the ligand-
activated receptors, translocating to the nucleus to regulate expression of downstream target 
genes 126,135,136. The name “SMAD” references its similarity to the SMA protein of C. elegans and 
the MAD (Mothers Against Decapentaplegic) protein in Drosophila 135. 
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There are three types of SMADs in mammals: receptor‐regulated SMADs (R‐SMADs), common‐
partner or comediator SMADs (Co‐SMADs), and inhibitory SMADs (I‐SMADs) 135,136,138. R-SMADS 
are the five SMADs that act as substrates for the TGFβ family of receptors (SMADs 1,2,3,5, and 
8) 135,136,138. SMAD4, the only Co-SMAD, serves as a common partner for R-SMADs 135,136,138. 
Lastly, SMAD6 and SMAD7 are I-SMADs, which interfere with the SMAD-receptor or SMAD-
SMAD interactions and function in the negative feedback loop 135,136,138.  
 
 
Figure 3.2 TGF and BMP Signaling  
Canonical signaling is initiated upon ligand binding to pairs of membrane receptor serine/threonine 
kinases (receptor types I and II), promoting the formation of a hetero-tetrameric receptor complex. 
Within this complex, the type 2 receptor phosphorylates and activates the type 1 receptor, which 
recruits and phosphorylates R-SMADs. Phosphorylated R-SMADs form heterooligomer complexes 
with SMAD4 for transcriptional regulation. This complex translocates to the nucleus where it interacts 
with different DNA-binding cofactors that confer target gene selectivity and regulation.  
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Activation of canonical signaling is initiated with TGFβ family ligands binding to a 
heterotetrameric receptor complex in the cell membrane 124,139. This receptor complex is 
comprised of two type 1 receptors and two type 2 receptors, which are transmembrane dual 
specificity kinases 140. Upon binding of ligand, the type 2 receptor phosphorylates and activates 
the type 1 receptor, which recruits and phosphorylates R-SMADs: SMAD2 and 3 for TGF 
receptors and ligands, and R-SMADs 1,5 and 8 for BMP receptors and ligands 124,139. This 
phosphorylation renders the R-SMADs active and able to form a heterooligomer complex with 
the ubiquitous SMAD4 124,126,129,130,135,136,138,139. The formation of this complex promotes nuclear 
translocation 124,135,136,138,139. Once in the nucleus, the R-SMAD/SMAD4 complex binds to DNA in 
cooperation with other transcription factors and cofactors to induce or repress gene 
transcription 124,135,136,140,141.  
  
miRNA Regulation of TGF Family Ligands 
One manner in which miRNAs exert their regulatory role is by directly targeting the TGFβ 
superfamily ligands (Table 3.1). miR-422a, for example, was shown to the target TGFβ2 3′ UTR 
in human osteosarcoma cells, which display decreased levels of miR-422a and enhanced 
expression of TGF2 142. miR-675, encoded within the paternally imprinted lncRNA H19, directly 
targets human TGF1143. Interestingly, miR-675-5p targets the TGF1 5’ UTR, whereas the -3p 
isoform targets within the coding region 143. Inhibition of miR-675 in human MSCs decreased 
Runx2 and osteocalcin RNAs 143. TGF3, on the other hand, is targeted by miR-140-3p 144. The 
expression of miR-140 is reduced in osteoblastic cells over expressing Wnt3a, suggesting a 
possible mechanism contributing to crosstalk between these two signaling pathways 144. TGF3 
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is also targeted by miR-29b, a pro-osteogenic miRNA that increases during osteoblastic 
differentiation 145. 
Similar to TGFβ, BMP2 can also be 
directly targeted by miRNAs, such as 
miR-17-5p and miR-106a, to inhibit 
osteogenesis 146. In this study, 
overexpression of miR-17-5p and 
miR-106a in human adipose-derived 
mesenchymal stem cells (hADSCs) 
resulted in downregulation of 
endogenous BMP2, suppression of 
osteogenesis, and a decrease in the 
expression of osteogenic genes such 
as Runx2, Osterix/SP7, alkaline 
phosphatase, Osteopontin, and 
Osteocalcin 146. Interestingly, while 
overexpression of miR-17-5p and miR-106a inhibits osteogenesis, it promotes adipogenesis, 
with a significant increase in oil red O staining lipid droplets and adipogenic gene expression 
(PPAR and C/EBPα) 146. These data suggest a role for miRNAs in balancing commitment of a 
common progenitor to either an osteoblastic or adipogenic fate. Further, miR-106b-5p can also 
target BMP2 (human placental stem cells). In a murine model of glucocorticoid-induced 
osteopenia, injection of lentivirus expressing a miR-106b inhibitor attenuated bone loss and 
Table 3.1 miRNA Regulation of Ligands 







































increased BMP2 mRNA in femurs. These data indicate that the targeting of BMP2 by miR-106b-
5p is conserved across species, and provide proof-of-concept for targeting miR-106 to prevent 
bone loss 147. 
BMP7 is also osteogenic, and this BMP is targeted by miR-542-3p. Calvarial osteoblasts 
transfected with miR-542 inhibitor had increased osteoblastic marker gene expression, and 
mice injected with miR-542-3p inhibitor displayed increased trabecular bone volume. 
Importantly, miR-542 inhibitor partially attenuated bone loss associated with ovariectomy, as 
well as deficits in bone mechanical properties 148.  
 
miRNA Regulation of Signaling Receptors 
Aside from targeting ligands, miRNAs can regulate osteoblastic differentiation by targeting 
type I and type II receptors needed to transduce signaling from TGFβ family ligands (Table 3.2). 
For example, miR-181 was shown to target TGFβRI/ALK-5 149. Overexpression of miR-181 in 
MC3T3 and C2C12 mouse mesenchymal cells decreased TGFR1 protein levels and upregulated 
osteoblastic marker gene expression, as well as alkaline phosphatase activity 149. Since TGFβ can 
inhibit terminal osteoblastic differentiation, miR-181-mediated downregulation of TGFβRI 
enhanced osteoblastic differentiation in these cell types 149. In addition, TGFR1 can also be 
targeted by miR-140-5p 150. Interestingly, both miR-181 and miR-141-5p are induced and highly 
expressed during a femoral fracture repair model in rats. However, a correlation between their 




TGFR2 can be targeted by miR-
17 and miR-20a, which share the 
same seed binding region, and are 
expressed from the miR-17~92 
cluster 151. TGF signaling plays a 
key role in palatal mesenchyme 
development, and ablation of 
TGFR2 in craniofacial neural crest 
results in cleft palate 159. The 
expression of miR-17 and -20a are 
decreased from E12 to E14 in 
mouse embryonic development, 
and control of TGFR2 levels by 
miRNAs may be important for 
normal craniofacial development 159. Similarly, TGFR2 can be targeted by miR-204-5p, a 
miRNA decreased during the osteogenic differentiation of human amnionic membrane-derived 
mesenchymal cells 152. 
 
As discussed previously, activin receptor signaling negatively regulates osteoblastic 
differentiation 160. The type I activin receptor, AcvR1b/ALK-4 can be targeted by miR-210 to 
promote osteoblast differentiation 153. Expression of miR-210 is induced by BMP4, and when 
Table 3.2. miRNA Regulation of Receptors 
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miR-494 BMPR2 C2C12 157 
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overexpressed in bone marrow stromal cell line ST2, miR-210 induced expression of osteogenic 
gene markers genes (Osterix, alkaline phosphatase, and Osteocalcin) 153. The type I receptor 
AcvR1/ALK2 is required for BMP7 signaling. This receptor is targeted by miR-208a-3p, a miRNA 
that is highly induced in mechanical unloading, a circumstance known to produce bone loss as 
well as a decrease in AcvR1 expression. In mice subjected to hind limb unloading, injection with 
miR-208a-3p inhibitor partially rescued bone loss 154. Further, miR-16 can negatively regulate 
osteoblastic differentiation by direct targeting of the type II activin receptor, AcvR2a. In this 
study, the authors utilized a miRNA delivery system containing nanohydroxyapatite (nHA) 
particles and collagen-nHA scaffolds to deliver antagomiR-16, which increased the relative 
levels of Runx2 and Osteocalcin, as well as calcium deposition 155. 
 
BMPR2 is targeted by several miRNAs, including mechanosensitive miR-494. This miRNA is 
induced in cultured mesenchymal cells subjected to simulated microgravity, as well as in bone 
from mice experiencing hindlimb suspension. Inhibition of miR-494 augmented BMP2-induced 
osteoblastic gene expression in vitro 157. BMPR2 is also targeted by miR-1187. Expression of this 
miRNA is decreased in BMP2-treated mouse calvarial osteoblasts in vitro, suggesting a feed-
forward loop to promote BMP signaling. Importantly, injection of mice with miR-1187 inhibitor 
decreased trabecular bone loss caused by ovariectomy 156. 
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miRNA Regulation of SMADs  
miRNAs can also regulate 
osteoblast differentiation and bone 
formation through direct targeting 
of signal transducing receptor 
SMADs (Table 3.3). For example, 
SMAD1 mediates signaling 
downstream of the BMP family 
ligands, and has been shown to be 
targeted by several  
miRNAs, including miR‐100 161. 
Overexpression of miR-100 
decreased SMAD1 levels and 
alkaline phosphatase activity (a 
marker of osteogenesis) in the 
MC3T3-E1 pre-osteoblastic cell line, 
suggesting that miR-100 acts as an 
endogenous negative regulator of 
differentiation 161. The miR-30 family 
also targets SMAD1, blunting BMP2-
induced osteoblastic differentiation 
162. 
Table 3.3. miRNA Regulation of SMADs 
miRNA Target Cell Type Reference 
miR-100 SMAD1 MC3T3-E1 161 
miR-30 
Family 










cancer cell lines 
166 






miR‐144‐3p SMAD4 C3H10T1/2 167 
miR-106-5p SMAD5 C2C12 168 
miR-17-5p SMAD5 MC3T3-E1 168 
miR-155 SMAD5 MC3T3-E1 169 






miR-16 SMAD5 hMSCs 155 
miR-21 SMAD7 MC3T3-E1 172,173 
miR‐590‐5p SMAD7 MG63 174 
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As discussed earlier, TGF signaling can have either pro- or anti-osteogenic effects, 
depending on cellular context; therefore miRNAs that directly target R-SMADs 2 and 3 may 
induce or inhibit osteoblastogenesis. For example, miR-23b was shown to target SMAD3 in 
MC3T3-E1 cells. The down regulation of miR-23b in cells treated with the inflammatory 
stimulus LPS was associated with increased SMAD3 and decreased osteoblastic differentiation 
163. In contrast, SMAD3 targeting by miR-221-5p in human bone marrow stromal cells was 
shown to have an inhibitory effect on osteoblastic differentiation 164. The differential impact of 
SMAD3 inhibition on osteoblast differentiation in these two studies is likely related to 
differences in the cell systems used, as well as likely effects of the miRNA inhibitors on targets 
other than SMAD3.  
 
There seem to be fewer studies on miRNAs targeting SMAD2 in the osteoblastic lineage. 
However, miR-10b was suggested to promote osteoblastogenesis at the expense of 
adipogenesis, in part by its ability to target SMAD2 165. miR-19-3p was shown to target SMAD2 
and SMAD4 in human prostate cancer cell lines 166. Since miR-19a is also expressed in 
osteoblasts, the miR-19/SMAD2/4 targeting interaction validated in prostate cancer is likely 
relevant for the osteoblast lineage as well 175. Similarly, miR-144-3p can regulate osteogenic 
differentiation and proliferation of MSCs by direct targeting of SMAD4 167. In this study, 
overexpression of miR-144-3p was shown to blunt osteogenic differentiation and inhibition of 
miR-144-3p reversed this process 167.  
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A number of studies established the suppression of osteogenic differentiation by miRNA 
targeting of SMAD5. For example, miR-106b-5p and miR-17-5p, which have the same seed 
binding region, target SMAD5 in mouse mesenchymal cells. Expression of these miRNAs is 
repressed during BMP2-induced osteogenesis in both C2C12 and MC3T3-E1 cells, suggesting a 
feed forward loop to promote osteoblastic differentiation. Further, delivery of antagomiR for 
either miR-106b-5p or miR-17-5p could partially attenuate bone loss in ovariectomized mice 
and increased SMAD5 RNA in bone 168. miR-155 also inhibited osteogenic differentiation by 
downregulating the translation of SMAD5 in MC3T3-E1 cells 169. In human periodontal ligament 
stem cells, miR-21-5p was shown to target SMAD5, contributing to the ability of this miRNA to 
inhibit osteoblastic differentiation. In this study, bioinformatics suggested that other members 
of the BMP signaling pathway could be potential miR-21-5p targets, but only SMAD5 was 
validated 171. Further, miR-16 negatively regulate osteoblastic differentiation by direct targeting 
of SMAD5. In this study, a miRNA delivery system consisting of nanohydroxyapatite (nHA) 
particles and collagen-nHA scaffolds was used to deliver antagomiR-16, which increased the 
relative levels of Runx2, Osteocalcin, and calcium deposition 155. Lastly, the expression of miR-
135a decreases in C2C12 cells treated with BMP2, and this miRNA targets SMAD5, contributing 
to the inhibitory effect of miR-135a on osteogenesis 170. 
 
On the other hand, targeting of inhibitory SMADs has been shown to promote osteogenic 
differentiation 3,172,173,174. For example, downregulation of SMAD7 by miR-21a-5p promotes 
osteogenic differentiation and increases matrix mineralization in MC3T3-E1 cells 172,173. It is 
intriguing that this miRNA also targets SMAD5, which transduces signaling downstream of 
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BMPR stimulation. The ability of one miRNA to target both positive and negative regulators in 
the same signaling pathway is not uncommon and supports the concept that miRNAs function 
to fine tune the amplitude and tempo of signaling. miR‐590‐5p can also promote osteogenic 
differentiation and target SMAD7 174. This miRNA is increased during the osteoblastic 
differentiation of both human and mouse MSCs. In this study, transfection of a human 
osteosarcoma cell line with a miR-590-5p mimic resulted in increased Runx2 protein and 
decreased SMAD7, as well as increased expression of osteoblast differentiation markers and 
calcium deposition 174. These data suggest that miR-590-5p attenuates SMAD7-mediated 
inhibition of osteoblast differentiation 174.  
 
Translational Implications  
A thorough understanding of key molecular mechanisms regulating osteoblast 
differentiation and function is crucial for the development of new strategies aimed at increasing 
bone formation. miRNAs are estimated to post-transcriptionally regulate more than 60% of 
mammalian genes 113. In the bone field, studies on miRNA-mediated gene regulation are 
increasing, defining their functional contribution to the mammalian skeletal system through the 
regulation of signaling pathways important for bone metabolism. This work highlights the 
potential clinical applications of miRNAs as orthobiologic agents 113. In particular, since delivery 
of BMP2 is presently used to promote bone formation in vivo, miRNAs regulating the BMP 
signaling pathway are of interest. Therefore, studies that identify novel miRNA-target 
interactions and those examining in vivo models of miRNA knock down or over expression are 
critical for providing rationale and proof-of-concept for miRNA-based therapeutics in the 
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management of skeletal disorders. Indeed, approximately 16 million bone fractures occur in the 
United States annually, of which 10-15% display either delayed healing or non-unions, which 
increase patient morbidity and mortality. Local delivery of miRNA-based therapeutics could 
help treat difficult fractures and accelerate normal physiological fracture repair 113.  
 
While naked miRNAs are prone to degradation, a number of viral and non-viral carriers 
could be utilized to protect, deliver, and increase the efficiency of miRNA‐based therapeutics 
113,114. An example of this strategy is the single injection of miRNA expressing plasmids enclosed 
in microbubbles over a fracture callus, followed by ultrasound to break the microbubbles and 
deliver the plasmid 176. Although viral vector-mediated delivery can result in stable and higher 
levels of transgene expression, they have drawbacks in that they can be immunogenic, toxic, 
and have higher production cost 113,115.  
 
Despite the fact that non-viral vectors or small RNAs are safer and nontoxic, they have 
lower transfection efficiencies 113,116. However, a number of studies describe biomaterials that 
can be used as miRNA‐delivery‐based scaffolds to increase transfection efficiencies. These 
include materials such as chitosan, calcium phosphate, peptides, nanoparticles, lipid‐based or 
polymeric‐based carriers, and polymeric hydrogels 113,117,118. Some of materials have already 
shown preclinical success in treating bone defects 113.  
 
There are a number of strategies for chemically stabilizing small RNA inhibitors 
(antagomiRs) or miRNA mimics (agomiRs) for delivery to cells or whole animals, and some of 
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these modified small RNAs are in phase 1 or 2 clinical trials for diseases including fibrosis and 
cancer 34,177,178,179. In regard to bone, some investigators have demonstrated the efficacy of 
periosteal injections of miRNA-based therapeutics at fracture sites in rodent models. These 
resulted in an acceleration of repair and decrease of callus width, as well as an increase in 
osteogenic marker genes and increased callus bone mineral density, respectively 113,176,180. 
microRNA sponges expressed in cells have also been used as competitive inhibitors of 
endogenous microRNAs 34,181. When transiently transfected into cells, vectors that encode for 
these sponges (which contain strong promoters and multiple tandem binding sites for a miRNA 
of interest) can inhibit miRNA function efficiently, although its effects are not sustained 34,181. In 
order to induce long-term suppression of miRNA, a decoy RNA system using lentiviral vectors 
containing RNA cassettes driven by RNA polymerase III could be utilized 34. Through additional 
optimization of the decoy’s secondary structures and the miRNA-binding site, this highly potent 
miRNA inhibitory system could be used for well over 1 month 34.   
 
Characterizing the function of individual miRNAs in skeletal tissue and their subsequent 
testing in pre-clinical models advances the utility/feasibility of miRNA-based therapeutics in the 
management of skeletal disorders and, in particular, bone defect repair. Presently, bone grafts 
are a predominant method used to treat bone defects, delayed unions or non-unions 182. 
Integration of grafts with host bone can be challenging, hence improving the osteointegration 
of these grafts is of utmost importance. To tackle this issue, bone grafting procedures have 
been shifting to include addition of various biological growth factors, such as BMPs, and have 
exhibited good bone formation and osteointegration 182. While use of growth factors presents a 
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clinical improvement, further applications are limited due to concerns regarding high costs, 
supraphysiological doses, and side effects 182. To circumvent these issues, a more complete 
understanding of miRNAs affecting the BMP signaling pathway is of considerable interest and 
could lead to the development of improved therapies for bone regeneration 183. It is possible 
that localized delivery of miRNA-based therapeutics can modulate the BMP signaling pathway 
to promote bone formation and/or decrease the amount of exogenous BMP used in the 
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Supplemental Table 1. Sequence for Tough Decoys. miR-433 and C. elegans miR-67 binding 
sites are underlined in miR-433 TuD and non-targeting TuD respectively. For the transgenic 
mouse, three miR-433 TuD were assembled (underlined) and DNA from the coding region of 
the C. elegans Cut3 gene (denoted by lower case letters) was used as spacer between the 






























Supplemental Table 2. PCR Cloning Primers. GenBank reference numbers for the Mus musculus genes of 
interests are included. Restriction sites are underlined.  

































































Proximal site  
attttACTAGTTTGGGATTTAAGTTCTCT
CCTGTTAC 
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